Faculty:

Hope Rugo, MD - Moderator
Clinical Professor of Medicine
Division of Hematology & Oncology
Director, Breast Cancer Clinical Trials Program
University of California San Francisco
San Francisco, CA


Michael Gnant, MD - Chair
Professor of Surgery
University of Vienna
Vienna, Austria


Pierfranco Conte, MD
Professor of Oncology
Modena School of Medicine
Director, Department of Oncology & Hematology
University Hospital of Modena
Modena, Italy


Michael Untch, MD
Professor of Gynecology, Gynecologic Oncology
Director of Breast Cancer Center
HELIOS Klinikum Berlin-Buch
Berlin, Germany


Christos Markopoulos, MD*
Medical School
University of Athens
Athens, Greece


*to be confirmed

17:45	Welcome & Introduction of Faculty	Hope Rugo, MD Michael Gnant, MD
17:45-18:10	Case #1-HER-2 Overexpressing Breast Cancer: Management of Disease Progression Following Trastuzumab	Pierfranco Conte, MD
18:10-18:15	Faculty Comments & Questions from Audience
18:15-18:40	Case #2-The Premenopausal Patient: Optimizing Adjuvant Systemic Therapy	Michael Gnant, MD
18:40-18:45	Faculty Comments & Questions from Audience
18:45-19:10	Case #3-Evaluating Novel Strategies for Managing Metastatic Breast Cancer	Michael Untch, MD
19:10-19:15	Faculty Comments & Questions from Audience
19:15-19:40	Case #4-Choosing Adjuvant Therapy for the Endocrine Responsive Postmenopausal Patient	Christos Markopoulos, MD
19:40-19:45	Concluding Remarks	Hope Rugo, MD Michael Gnant, MD

Target Audience
This activity has been designed to meet the educational needs of medical, surgical, and radiation oncologists, as well as allied oncology healthcare professionals who treat breast cancer.


Needs Assessment
The treatment of breast cancer remains a challenge for oncologists despite recent advances in the management of this heterogeneous disease. Now, in the era of molecular biology, it is important to tailor therapy for each individual patient. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient and tumor specific considerations. While difficult, these decisions require knowledge of current clinical and experimental data in order appropriately integrate novel therapeutic agents and treatment strategies into everyday clinical practice. This educational symposium provides breast cancer physicians with state of the art therapeutic strategies in different clinical situations and the opportunity to discuss the optimal treatment options with renowned specialists in the field.


Learning Objectives
Upon completion of this educational activity, participants should be better able to:

• Evaluate treatment options for HER-2 positive patients following progression after adjuvant trastuzumab therapy
• Review optimal treatment options for triple-negative breast cancer
• Discuss best endocrine treatment modalities for postmenopausal patients with hormone receptor positive early breast cancer
• Identify unanswered clinical questions regarding the optimal use of endocrine agents for the treatment of hormone-sensitive breast cancer